These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8105596)

  • 41. SB-258741: a 5-HT7 receptor antagonist of potential clinical interest.
    Pouzet B
    CNS Drug Rev; 2002; 8(1):90-100. PubMed ID: 12070528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 May; 420(2-3):113-7. PubMed ID: 11408032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New therapeutic possibilities with drugs affecting serotonin receptors].
    Spigset O
    Tidsskr Nor Laegeforen; 1992 May; 112(13):1700-4. PubMed ID: 1509427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can 5-HT3 antagonists contribute toward the treatment of schizophrenia?
    Ellenbroek BA; Prinssen EP
    Behav Pharmacol; 2015 Feb; 26(1-2):33-44. PubMed ID: 25356732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Therapeutic gap when it comes to behavioral symptoms and psychoses among the elderly].
    Nygaard HA
    Tidsskr Nor Laegeforen; 2004 Oct; 124(19):2515. PubMed ID: 15477898
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.
    Talley NJ
    Aliment Pharmacol Ther; 1992 Jun; 6(3):273-89. PubMed ID: 1600046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants.
    Levy AD; Van de Kar LD
    Life Sci; 1992; 51(2):83-94. PubMed ID: 1352027
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.
    Squires RF; Saederup E
    Neurochem Res; 1999 May; 24(5):659-67. PubMed ID: 10344595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Robalzotan AstraZeneca.
    Mucke HA
    Curr Opin Investig Drugs; 2000 Oct; 1(2):236-40. PubMed ID: 11249580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clozapine, SCH 23390 and alpha-flupenthixol but not haloperidol attenuate acute phencyclidine-induced disruption of conditional discrimination performance.
    Dunn MJ; Killcross S
    Psychopharmacology (Berl); 2007 Mar; 190(4):403-14. PubMed ID: 17237918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential therapeutic targets for neurokinin-1 receptor antagonists.
    Duffy RA
    Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analgesic effects of 5-HT3 receptor antagonists.
    Riering K; Rewerts C; Zieglgänsberger W
    Scand J Rheumatol Suppl; 2004; 119():19-23. PubMed ID: 15515407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications.
    Simonsen KB; Juhl K; Steiniger-Brach B; Nielsen SM
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):379-88. PubMed ID: 20597024
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical pharmacology of the benzodiazepines].
    Honorato Pérez JM; Azanza Perea JR; Cuena Boy R
    Rev Med Univ Navarra; 1982 Dec; 26(4):225-8. PubMed ID: 6134329
    [No Abstract]   [Full Text] [Related]  

  • 58. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V; Herrling P
    Neurodegener Dis; 2009; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract]   [Full Text] [Related]  

  • 59. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
    Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
    CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serotonin receptor antagonists for the prevention and treatment of pruritus, nausea, and vomiting in women undergoing cesarean delivery with intrathecal morphine: a systematic review and meta-analysis.
    George RB; Allen TK; Habib AS
    Anesth Analg; 2009 Jul; 109(1):174-82. PubMed ID: 19535708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.